Boston Scientific (NYSE:BSX) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Boston Scientific (NYSE:BSX) in a research note published on Monday morning,Benzinga reports. They currently have a $97.00 price objective on the medical equipment provider’s stock.

Several other brokerages have also weighed in on BSX. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. UBS Group lowered their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Finally, Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Boston Scientific Stock Performance

Shares of BSX stock opened at $62.90 on Monday. The company has a market cap of $93.49 billion, a P/E ratio of 32.42, a PEG ratio of 1.07 and a beta of 0.69. The firm has a fifty day moving average price of $76.94 and a 200 day moving average price of $90.32. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific has a 12 month low of $61.24 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts predict that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BSX. Vanguard Group Inc. increased its stake in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp boosted its stake in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after buying an additional 920,495 shares during the period. Capital World Investors grew its holdings in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the last quarter. Norges Bank purchased a new position in shares of Boston Scientific during the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley increased its position in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Asurys fluid management system gives Boston Scientific another regulatory win and supports growth in perioperative/OR product offerings. Boston Scientific wins FDA clearance for fluid management system
• Positive Sentiment: Strong HI-PEITHO trial results for the EKOS endovascular system (positive readout reported) bolster the company’s pulmonary embolism franchise and provide clinical momentum for EKOS adoption. Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
• Positive Sentiment: Several analysts reaffirm buy/outperform ratings and high price targets (Needham, TD Cowen, RBC), reflecting confidence in long-term growth drivers like Watchman FLX and diversified product mix. Buy Rating on Boston Scientific’s Watchman FLX
• Neutral Sentiment: Company set an investors’ conference call for the Q1 2026 results (April 22), which will be a key event for management to clarify guidance, procedure trends and margin outlook. Boston Scientific announces conference call
• Neutral Sentiment: Analysts expect single-digit EPS growth for Q1 2026; Q1 results and any guidance update will likely drive near-term volatility but may not change the long-term thesis. Boston Scientific’s Q1 2026 Earnings: What to Expect
• Negative Sentiment: Mixed/underwhelming clinical data for the Watchman device (conflicting trial readouts) is the proximate trigger for today’s sell-off as investors reprice stroke-prevention growth expectations. Boston Scientific Falls After Underwhelming Trial Results
• Negative Sentiment: Raymond James downgraded BSX and cut its price target, and Goldman trimmed its target as well — analyst downgrades and lower PTs pressured sentiment and valuation multiples. Shares Plunge After Raymond James Downgrade
• Negative Sentiment: Heightened legal/regulatory overhang — multiple investor alerts and class-action filings tied to prior disclosures are creating uncertainty and may keep pressure on the stock until resolved. BSX Investor Alert: Securities Fraud Lawsuit

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.